Meridian wins Cambridge Biotech enteric product line
This article was originally published in Clinica
Executive Summary
Meridian Diagnostics (US) is to buy Cambridge Biotech's enteric product line for $5.5 million cash. The deal replaces an agreement formed with Carter-Wallace in May for the purchase of the products for $4.5 million cash (see Clinica No 705, p 1). Cambridge Biotech was instructed by the bankruptcy court to open the offer to bidding.